Rheumatology: Current Research
Open Access

Autoimmune Illnesses and Pathophysiology of People with Scleroderma

Jane Austen^{* *}Correspondence: Jane Austen, Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, Email:

Author info »

About the Study

Skin, blood vessels, muscles, and internal organs may change as a result of the autoimmune illnesses known as scleroderma. The illness may only affect the skin or it may affect other organs as well. Areas of thickened skin, stiffness, fatigue, and impaired blood flow to the fingers or toes after exposure to cold are possible symptoms. One kind of the illness, called CREST syndrome, is characterized by calcium deposits, Raynaud's syndrome, esophageal issues, thickening of the finger and toe skin, and regions of small, dilated blood vessels.

Although the cause is uncertain, it might be brought on by an unusual immunological response. Family history, specific genetic traits, and silica exposure are all risk factors. The underlying mechanism, which is thought to be caused by the immune system targeting healthy tissues, involves the aberrant formation of connective tissue. A skin sample or blood tests may be used to support a diagnosis based on symptoms.

Although there is no known cure, therapy may lessen symptoms. Corticosteroids, methotrexate, and non-steroidal antiinflammatory medicines are among the medications utilised (NSAIDs). The severity of the condition determines the outcome. The life expectancy of those with localised disease is typically average. Depending on the subtype, life expectancy can be impacted in patients with systemic disease. Complications of the heart, lungs, or digestive system frequently result in death. Each year, three out of every 100,000 persons get the systemic form. The illness typically manifests in middle age. Men are less likely to be affected than women. The word comes from the Greek words for "skin" and "hard," respectively.

Pathophysiology

Increased collagen synthesis, which causes sclerosis, damage to small blood vessels, activation of T lymphocytes, and formation of altered connective tissue are its defining characteristics. It starts with a vasculature-level inciting event, most likely at the endothelium level. Although the trigger has not yet been identified, it might be a virus, oxidative stress, or an autoimmune condition. Following endothelial cell loss and death, there is vascular leakiness, which first appears clinically as tissue oedema in the early stages. It is primarily a Th1- and Th17- mediated illness at this point.

After that, poor angiogenesis and impaired vasculogenesis (fewer endothelial progenitor cells), perhaps due to the presence of antiendothelinal cell antibodies, further weaken the vasculature (AECA). Despite this decreased angiogenesis, individuals with the disease frequently have higher levels of pro-angiogenic growth factors such PDGF and VEGF. Vasoconstriction results when the ratio of vasodilation to vasoconstriction shifts. Additionally, the damaged endothelium aids in the formation of blood clots, ischemia-reperfusion injury, and the production of reactive oxygen species. Th2 polarity is a feature of these latter phases.

In order to draw in leucocytes and trigger innate and adaptive immune responses, the damaged endothelium upregulates adhesion molecules and chemokines. This results in loss of tolerance to a variety of oxidized antigens, including topoisomerase I, as well as the development of these immune responses. The development of B cells into plasma cells intensifies the autoimmune aspect of the illness. Th2 cells, one of the subgroups of T cells that develop, are essential for tissue fibrosis. Anti-topoisomerase 1 antibodies in turn promote the generation of type I interferon.

Myofibroblasts are produced by the recruitment and activation of fibroblasts by a variety of cytokines and growth factors. In numerous investigations of people with scleroderma, Dysregulated Transforming Growth Factor (TGF) signalling in fibroblasts and myofibroblasts has been noted. Fibrosis is brought on by excessive collagen and other associated protein deposits caused by activated fibroblasts and myofibroblasts. This stage involves B cells because they produce IL-6 and TGF-, which slow down the breakdown of collagen and boost the formation of extracellular matrix. The pathophysiology of fibrosis is thought to be mediated by endothelin signalling. Vitamin D is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted, and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system.